Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing

Journal of Clinical Oncology

Volumn 32, Issue 2, 2014, Pages 90-100

  Buchanan, Daniel D ^a   Tan, Yen Y ^a,b   Walsh, Michael D ^a   Clendenning, Mark ^a   Metcalf, Alexander M ^a   Ferguson, Kaltin ^a   Arnold, Sven T ^a   Thompson, Bryony A ^a   Lose, Felicity A ^a   Parsons, Michael T ^a   Walters, Rhiannon J ^a   Pearson, Sally Ann ^a   Cummings, Margaret ^b   Oehler, Martin K ^c   Blomfield, Penelope B ^g   Quinn, Michael A ^d   Kirk, Judy A ^e   Stewart, Colin J ^f   Obermair, Andreas ^b   Young, Joanne P ^a   Webb, Penelope M ^a   Spurdle, Amanda B ^a   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ROYAL WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f KING EDWARD MEMORIAL HOSPITAL   (Australia)

^g ROYAL HOBART HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MLH1; ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; G T MISMATCH BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; COLORECTAL CANCER; DNA METHYLATION; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; MISMATCH REPAIR; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEOPLASM; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SECOND DEGREE RELATIVE; AUSTRALIA; COHORT ANALYSIS; EARLY DIAGNOSIS; ENDOMETRIUM TUMOR; GENETICS; HEALTH SURVEY; METABOLISM; METHODOLOGY; MIDDLE AGED; MUTATION; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; COHORT STUDIES; DNA METHYLATION; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EARLY DETECTION OF CANCER; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; POPULATION SURVEILLANCE;

EID: 84897018139     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.2129     Document Type: Article

References (70)

1. Bonadona V, Bonaïti B, Olschwang S, et al: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305:2304-2310, 2011
2. Engel C, Loeffler M, Steinke V, et al: Risks of less common cancers in proven mutation carriers with Lynch syndrome. J Clin Oncol 30:4409-4415, 2012
3. Win AK, Young JP, Lindor NM, et al: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J Clin Oncol 30:958-964, 2012
4. Vasen HF, Blanco I, Aktan-Collan K, et al: Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut 62:812-823, 2013
5. Dowty JG, Win AK, Buchanan DD, et al: Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat 34:490-497, 2013
6. Koornstra JJ, Mourits MJ, Sijmons RH, et al: Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 10:400-408, 2009
7. Win AK, Lindor NM, Young JP, et al: Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 104:1363-1372, 2012
8. Schmeler KM, Lynch HT, Chen LM, et al: Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261-269, 2006 (Pubitemid 43113031)
9. Kwon JS, Sun CC, Peterson SK, et al: Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113:326-335, 2008
10. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, et al: Ten years after mutation testing for Lynch syndrome: Cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793-4797, 2009
11. Lu KH, Loose DS, Yates MS, et al: Prospective, multi-center randomized intermediate biomarker study of oral contraceptive vs. depo-provera for prevention of endometrial cancer in women with Lynch Syndrome. Cancer Prev Res (Phila) 6:774-781, 2013
12. Vasen HF, Watson P, Mecklin JP, et al: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999 (Pubitemid 29258894)
13. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004 (Pubitemid 38256271)
14. Lancaster JM, Powell CB, Kauff ND, et al: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159-162, 2007 (Pubitemid 47575743)
15. Tan YY, McGaughran J, Ferguson K, et al: Improving identification of lynch syndrome patients: A comparison of research data with clinical records. Int J Cancer 132:2876-2883, 2013
16. Tranø G, Wasmuth HH, Sjursen W, et al: Awareness of heredity in colorectal cancer patients is insufficient among clinicians: A Norwegian population-based study. Colorectal Dis 11:456-461, 2009
17. Lanceley A, Eagle Z, Ogden G, et al: Family history and women with ovarian cancer: Is it asked and does it matter?: An observational study. Int J Gynecol Cancer 22:254-259, 2012
18. Hampel H, Frankel WL, Martin E, et al: Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851-1860, 2005
19. Sjursen W, Haukanes BI, Grindedal EM, et al: Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet 47:579-585, 2010
20. Tranø G, Sjursen W, Wasmuth HH, et al: Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: A Norwegian population-based study. Br J Cancer 102:482-488, 2010
21. Ryan P, Mulligan AM, Aronson M, et al: Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 118:681-688, 2012
22. Morrison J, Bronner M, Leach BH, et al: Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: From the revised Bethesda guidelines to a universal approach. Scand J Gastroenterol 46:1340-1348, 2011
23. Moreira L, Balaguer F, Lindor N, et al: Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308:1555-1565, 2012
24. Beamer LC, Grant ML, Espenschied CR, et al: Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30:1058-1063, 2012
25. Kalloger SE, Allo G, Mulligan AM, et al: Use of mismatch repair immunohistochemistry and microsatellite instability testing: Exploring Canadian practices. Am J Surg Pathol 36:560-569, 2012
26. Clarke BA, Cooper K: Identifying lynch syndrome in patients with endometrial carcinoma: Shortcomings of morphologic and clinical schemas. Adv Anat Pathol 19:231-238, 2012
27. Steinhagen E, Shia J, Markowitz AJ, et al: Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection. J Am Coll Surg 214:61-67, 2012
28. Moline J, Mahdi H, Yang B, et al: Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. Gynecol Oncol 130:121-126, 2013
29. Shia J: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part I: The utility of immunohistochemistry. J Mol Diagn 10:293-300, 2008
30. Hampel H: Point: Justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer. J Natl Compr Canc Netw 8:597-601, 2010
31. Parsons MT, Buchanan DD, Thompson B, et al: Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: A literature review assessing utility of tumour features for MMR variant classification. J Med Genet 49:151-157, 2012
32. Backes FJ, Leon ME, Ivanov I, et al: Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. Gynecol Oncol 114:486-490, 2009
33. Hampel H, Frankel W, Panescu J, et al: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810-7817, 2006 (Pubitemid 44289242)
34. Bruegl AS, Djordjevic B, Urbauer DL, et al: Utility of MLH1 methylation analysis in the clinical evaluation of Lynch syndrome in women with endometrial cancer. Curr Pharm Des [epub ahead of print on July 19, 2013]
35. Thompson BA, Greenblatt MS, Vallee MP, et al: Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat 34:255-265, 2013
36. Walsh MD, Cummings MC, Buchanan DD, et al: Molecular, pathologic, and clinical features of early-onset endometrial cancer: Identifying presumptive Lynch syndrome patients. Clin Cancer Res 14:1692-1700, 2008 (Pubitemid 351469453)
37. Arnold S, Buchanan DD, Barker M, et al: Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat 30:757-770, 2009
38. Clendenning M, Macrae FA, Walsh MD, et al: Absence of PMS2 mutations in colon-CFR participants whose colorectal cancers demonstrate unexplained loss of MLH1 expression. Clin Genet 83:591-593, 2013
39. Ogino S, Kawasaki T, Brahmandam M, et al: Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8:209-217, 2006 (Pubitemid 43811244)
40. Thompson BA, Spurdle AB, Plazzer J-P, et al: Application of a five-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants lodged on the InSiGHT locus-specific database. Nat Genet (in press)
41. Lu KH, Schorge JO, Rodabaugh KJ, et al: Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25:5158-5164, 2007 (Pubitemid 350232246)
42. Heald B, Plesec T, Liu X, et al: Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing Lynch syndrome in a large academic medical center. J Clin Oncol 31:1336-1340, 2013
43. Berends MJ, Wu Y, Sijmons RH, et al: Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 21:4364-4370, 2003 (Pubitemid 46621813)
44. Kwon JS, Carey MS, Goldie SJ, et al: Cost-effectiveness analysis of treatment strategies for stage I and II endometrial cancer. J Obstet Gynaecol Can 29:131-139, 2007
45. Cohn DE, Pavelka JC, Frankel WL, et al: Correlation between patient weight and defects in DNA mismatch repair: Is this the link between an increased risk of previous cancer in thinner women with endometrial cancer? Int J Gynecol Cancer 18:136-140, 2008
46. Piperi C, Farmaki E, Vlastos F, et al: DNA methylation signature analysis: How easy is it to perform? J Biomol Tech 19:281-284, 2008
47. How Kit A, Nielsen HM, Tost J: DNA methylation based biomarkers: Practical considerations and applications. Biochimie 94:2314-2337, 2012
48. Gausachs M, Mur P, Corral J, et al: MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: A cost-effectiveness study. Eur J Hum Genet 20:762-768, 2012
49. Poynter JN, Siegmund KD, Weisenberger DJ, et al: Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17:3208-3215, 2008
50. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al: Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 61:865-872, 2012
51. Metcalf AM, Spurdle AB: Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: A literature review. Fam Cancer [epub ahead of print on July 24, 2013]
52. Devlin LA, Graham CA, Price JH, et al: Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than hereditary non polyposis colorectal cancer cohorts. Ulster Med J 77:25-30, 2008 (Pubitemid 351148703)
53. Goodfellow PJ, Buttin BM, Herzog TJ, et al: Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 100:5908-5913, 2003 (Pubitemid 36576906)
54. Broaddus RR, Lynch HT, Chen LM, et al: Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma. Cancer 106:87-94, 2006 (Pubitemid 43032552)
55. Garg K, Leitao MM Jr, Kauff ND, et al: Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 33:925-933, 2009
56. Resnick KE, Hampel H, Fishel R, et al: Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 114:128-134, 2009
57. Nagasaka T, Rhees J, Kloor M, et al: Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res 70:3098-3108, 2010
58. Clendenning M, Buchanan DD, Walsh MD, et al: Mutation deep within an intron of MSH2 causes Lynch syndrome. Fam Cancer 10:297-301, 2011
59. Morak M, Koehler U, Schackert HK, et al: Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. J Med Genet 48:513-519, 2011
60. Sourrouille I, Coulet F, Lefevre JH, et al: Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam Cancer 12:27-33, 2013
61. Boland CR: The mystery of mismatch repair deficiency: Lynch or Lynch-like? Gastroenterology 144:868-870, 2013
62. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 (Pubitemid 46224239)
63. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875, 2011
64. Buecher B, Cacheux W, Rouleau E, et al: Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis 45:441-449, 2013
65. Nelson GS, Pink A, Lee S, et al: MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol 131:309-314, 2013
66. Allo G, Bernardini MQ, Wu RC, et al: ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol 10.1038/modpathol.2013.144 [epub ahead of print on July 26, 2012]
67. Qureshi N, Wilson B, Santaguida P, et al: Collection and use of cancer family history in primary care. Evid Rep Technol Assess (Full Rep):1-84, 2007
68. de Leeuw WJ, Dierssen J, Vasen HF, et al: Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 192:328-335, 2000
69. Sobczuk A, Romanowicz-Makowska H, Smolarz B, et al: Microsatellite instability (MSI) and MLH1 and MSH2 protein expression analysis in postmenopausal women with sporadic endometrial cancer. J Exp Clin Cancer Res 26:369-374, 2007 (Pubitemid 47584813)
70. Mangold E, Pagenstecher C, Friedl W, et al: Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol 207:385-395, 2005 (Pubitemid 43025686)